Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2019 Jul 4

PMID 31266220

Citations 3

Authors

Bozena Karolewicz

Agata Gorniak

Dominik M Marciniak

Igor Mucha

Affiliations

Soon will be listed here.

Abstract

The proposed study examined the characterization and stability of solid-state amorphous imatinib mesylate (IM) after 15 months under controlled relative humidity (60 ± 5%) and temperature (25 ± 2 °C) conditions. After 2 weeks, and 1, 3, 6, and 15 months, the samples were characterized using differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), X-ray powder diffractometry (XRPD), attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR) and scanning electron microscopy (SEM). Additionally, the amorphous form of imatinib mesylate was obtained via supercooling of the melt in a DSC apparatus, and aged at various temperatures (3, 15, 25 and 30 °C) and time periods (1-16 h). Glass transition and enthalpy relaxation were used to calculate molecular-relaxation-time parameters. The Kohlrausch-Williams-Watts (KWW) equation was applied to fit the experimental enthalpy-relaxation data. The mean molecular-relaxation-time constant () increased with decreasing ageing temperature. The results showed a high stability of amorphous imatinib mesylate adequate to enable its use in solid dosage form.

Citing Articles

Stability Studies of Amorphous Ibrutinib Prepared Using the Quench-Cooling Method and Its Dispersions with Soluplus.

Mucha I, Karolewicz B, Gorniak A Polymers (Basel). 2024; 16(14).

PMID: 39065278 PMC: 11280989. DOI: 10.3390/polym16141961.

An Investigation of the Impact of Precipitation Temperature and Filter Cake Thickness on the Physical Stability of Amorphous Solids: A Case Study.

Li Z, Liao X, Gong Z, Zhang B, Nawaz A Molecules. 2024; 29(10).

PMID: 38792188 PMC: 11123877. DOI: 10.3390/molecules29102327.

Nanohydroxyapatite-Mediated Imatinib Delivery for Specific Anticancer Applications.

Sobierajska P, Serwotka-Suszczak A, Szymanski D, Marycz K, Wiglusz R Molecules. 2020; 25(20).

PMID: 33050306 PMC: 7587182. DOI: 10.3390/molecules25204602.

References

Craig D, Royall P, Kett V, Hopton M . The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems. Int J Pharm. 1999; 179(2):179-207. DOI: 10.1016/s0378-5173(98)00338-x. View

Hancock B, Parks M . What is the true solubility advantage for amorphous pharmaceuticals?. Pharm Res. 2000; 17(4):397-404. DOI: 10.1023/a:1007516718048. View

Druker B, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344(14):1031-7. DOI: 10.1056/NEJM200104053441401. View

Yu L . Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001; 48(1):27-42. DOI: 10.1016/s0169-409x(01)00098-9. View

Hancock B, Carlson G, Ladipo D, Langdon B, Mullarney M . Comparison of the mechanical properties of the crystalline and amorphous forms of a drug substance. Int J Pharm. 2002; 241(1):73-85. DOI: 10.1016/s0378-5173(02)00133-3. View

Zhou D, Zhang G, Law D, Grant D, Schmitt E . Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility. J Pharm Sci. 2002; 91(8):1863-72. DOI: 10.1002/jps.10169. View

Demetri G, von Mehren M, Blanke C, Van Den Abbeele A, Eisenberg B, Roberts P . Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347(7):472-80. DOI: 10.1056/NEJMoa020461. View

Lassila M, Allen T, Cao Z, Thallas V, Jandeleit-Dahm K, Candido R . Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol. 2004; 24(5):935-42. DOI: 10.1161/01.ATV.0000124105.39900.db. View

Vranic E . Amorphous pharmaceutical solids. Bosn J Basic Med Sci. 2005; 4(3):35-9. PMC: 7245478. DOI: 10.17305/bjbms.2004.3383. View

10.

Zohlnhofer D, Hausleiter J, Kastrati A, Mehilli J, Goos C, Schuhlen H . A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. J Am Coll Cardiol. 2005; 46(11):1999-2003. DOI: 10.1016/j.jacc.2005.07.060. View

11.

Yoshioka S, Aso Y . Correlations between molecular mobility and chemical stability during storage of amorphous pharmaceuticals. J Pharm Sci. 2007; 96(5):960-81. DOI: 10.1002/jps.20926. View

12.

Kim J, Kim M, Park H, Jin S, Lee S, Hwang S . Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. Int J Pharm. 2008; 359(1-2):211-9. DOI: 10.1016/j.ijpharm.2008.04.006. View

13.

Lemm D, Muegge L, Hoeffken K, Aklan T, Mentzel T, Thorwarth M . Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report. Oral Maxillofac Surg. 2008; 12(4):209-13. DOI: 10.1007/s10006-008-0130-8. View

14.

Graeser K, Patterson J, Zeitler J, Gordon K, Rades T . Correlating thermodynamic and kinetic parameters with amorphous stability. Eur J Pharm Sci. 2009; 37(3-4):492-8. DOI: 10.1016/j.ejps.2009.04.005. View

15.

Zhou D, Zhang G, Law D, Grant D, Schmitt E . Thermodynamics, molecular mobility and crystallization kinetics of amorphous griseofulvin. Mol Pharm. 2009; 5(6):927-36. DOI: 10.1021/mp800169g. View

16.

Tolomeo M, Dieli F, Gebbia N, Simoni D . Tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Anticancer Agents Med Chem. 2009; 9(8):853-63. DOI: 10.2174/187152009789124637. View

17.

Cortes J, Baccarani M, Guilhot F, Druker B, Branford S, Kim D . Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor.... J Clin Oncol. 2009; 28(3):424-30. PMC: 4979244. DOI: 10.1200/JCO.2009.25.3724. View

18.

Rutkowski P, Van Glabbeke M, Rankin C, Ruka W, Rubin B, Debiec-Rychter M . Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010; 28(10):1772-9. PMC: 3040044. DOI: 10.1200/JCO.2009.25.7899. View

19.

Shete G, Puri V, Kumar L, Bansal A . Solid state characterization of commercial crystalline and amorphous atorvastatin calcium samples. AAPS PharmSciTech. 2010; 11(2):598-609. PMC: 2902319. DOI: 10.1208/s12249-010-9419-7. View

20.

Stacchiotti S, Pedeutour F, Negri T, Conca E, Marrari A, Palassini E . Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. Int J Cancer. 2010; 129(7):1761-72. DOI: 10.1002/ijc.25826. View